Genfit S.A. (EPA: GNFT)
France
· Delayed Price · Currency is EUR 4.150
-0.005 (-0.12%)
Nov 19, 2024, 5:35 PM CET
Genfit Revenue
Genfit had revenue of 61.10M EUR in the half year ending June 30, 2024, with 403.23% growth. This brings the company's revenue in the last twelve months to 80.47M, up 175.45% year-over-year. In the year 2023, Genfit had annual revenue of 34.48M with 31.38% growth.
Revenue (ttm)
80.47M
Revenue Growth
+175.45%
P/S Ratio
2.49
Revenue / Employee
476.18K
Employees
159
Market Cap
200.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 34.48M | 8.24M | 31.38% |
| Dec 31, 2022 | 26.25M | -59.11M | -69.25% |
| Dec 31, 2021 | 85.36M | 76.67M | 883.14% |
| Dec 31, 2020 | 8.68M | -30.29M | -77.72% |
| Dec 31, 2019 | 38.97M | 31.61M | 429.18% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 48.45B |
| EssilorLuxottica Société anonyme | 25.83B |
| Sartorius Stedim Biotech S.A. | 2.74B |
| bioMérieux S.A. | 3.81B |
| Ipsen S.A. | 3.44B |
| Eurofins Scientific SE | 6.72B |
| Virbac SA | 1.34B |
| Ramsay Générale de Santé SA | 5.01B |
Genfit News
- 7 days ago - GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 - GlobeNewsWire
- 13 days ago - Genfit reports 9M results - Seeking Alpha
- 13 days ago - GENFIT Reports Third Quarter 2024 Financial Information - GlobeNewsWire
- 2 months ago - Top 4 Health Care Stocks That May Keep You Up At Night - Benzinga
- 2 months ago - GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval - GlobeNewsWire
- 2 months ago - Genfit GAAP EPS of €0.53, revenue of €61.2M - Seeking Alpha
- 4 months ago - GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis - GlobeNewsWire
- 4 months ago - GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - GlobeNewsWire